The study and its comparison
PANTHEON randomized 1,006 adults with moderate-to-severe COPD at Chinese hospitals to NAC 600 mg twice daily or placebo for one year. The primary analysis included 482 participants per group. [1]
Annual exacerbation rates were 1.16 versus 1.49 per patient-year, favoring NAC. Adverse events were reported in both groups; the study did not establish that every lung condition responds similarly. [1]
What the finding establishes
A recurrent-event rate is not the percentage of people cured. Hainan Zambon Pharmaceutical funded the study; full conflicts were not established from the abstract. The finding concerns long-term prevention in the studied setting, not replacement of inhalers or urgent care during an exacerbation. [1]
A hypothetical distinction
Imagine several exacerbations occur in one person. Events per patient-year and people with an event have different denominators.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.